ERBB2 and gastric cancer: The initial phase III ToGA trial in 2010 enrolled 584 patients (GC, n = 478; GEJ, n = 106) with HER-2 overexpression by IHC or amplification by FISH to either trastuzumab (HER-2 targeted mAb) with chemotherapy (FP or cisplatin + capecitabine) or chemotherapy alone in the first-line setting.